Preferred Label : Darzalex;
Origin ID : M000613227;
Related record
https://www.has-sante.fr/jcms/p_3334268/fr/darzalex-daratumumab-myelome-multiple
2022
France
evaluation of the transparency committee
multiple myeloma
daratumumab
Myeloma
Darzalex
Myeloma
daratumumab
multiple myeloma
---
https://www.has-sante.fr/jcms/p_3320599/fr/darzalex-daratumumab-amylose-systemique-a-chaines-legeres
2022
France
evaluation of the transparency committee
Darzalex
amyloid deposition, nos
chain
daratumumab
daratumumab
amyloidosis, nos
amylose
---
https://has-sante.fr/jcms/p_3292242/fr/decision-n-2021-0262/dc/sem-du-7-octobre-2021-du-college-de-la-haute-autorite-de-sante-constatant-l-impact-significatif-du-produit-darzalex-daratumumab-1800-mg-sur-les-depenses-de-l-assurance-maladie
2021
France
public health guidelines
Darzalex
Insurance
health
health expenditures
7-methylbenzanthracene
daratumumab
daratumumab
disease, nos
Diseases
expenditures
schools
insurance, health
Disease
---
https://has-sante.fr/jcms/p_3183497/fr/darzalex-daratumumab
2020
France
evaluation of the transparency committee
daratumumab
Darzalex
daratumumab
---
https://has-sante.fr/jcms/p_3183488/fr/darzalex-daratumumab
2020
France
evaluation of the transparency committee
indicators
indicators and reagents
daratumumab
daratumumab
Darzalex
traction
indication of
---
https://www.has-sante.fr/portail/jcms/c_2967184/fr/darzalex
2019
false
false
false
France
adult
multiple myeloma
antineoplastic combined chemotherapy protocols
infusions, intravenous
antineoplastic agents
daratumumab
Bortezomib
melphalan
prednisone
survival analysis
treatment outcome
evaluation of the transparency committee
Darzalex
daratumumab
antibodies, monoclonal
daratumumab
antibodies, monoclonal
---
